Security Snapshot

Allogene Therapeutics, Inc. - Common Stock (ALLO) Institutional Ownership

CUSIP: 019770106

13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

169

Shares (Excl. Options)

162,689,328

Price

$1.37

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
ALLO on Nasdaq
Shares outstanding
228,416,724
Price per share
$2.44
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
162,689,328
Total reported value
$222,787,071
% of total 13F portfolios
0%
Share change
+102,529
Value change
+$240,755
Number of holders
169
Price from insider filings
$2.44
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • ALLO - Allogene Therapeutics, Inc. - Common Stock is tracked under CUSIP 019770106.
  • 169 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 169 to 10 between Q4 2025 and Q1 2026.
  • Reported value moved from $222,787,071 to $437,853.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 169 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 019770106?
CUSIP 019770106 identifies ALLO - Allogene Therapeutics, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Allogene Therapeutics, Inc. - Common Stock (ALLO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PFIZER INC 9% $30,183,895 22,032,040 Pfizer Inc. 06 Nov 2025
CITADEL ADVISORS LLC 6.1% $15,091,828 13,346,151 Kenneth Griffin 09 Jul 2025
Belldegrun Arie 5.8% +3.3% $18,149,993 +$794,362 13,248,170 +4.6% Arie Belldegrun, M.D. 31 Dec 2025
Chang David D 5.2% +6% $16,578,676 +$1,186,838 12,101,223 +7.7% David D. Chang, M.D., Ph.D. 31 Dec 2025
BlackRock, Inc. 5.3% $17,633,122 11,450,079 BlackRock, Inc. 31 Mar 2025
Lynx1 Capital Management LP 5.2% $16,747,073 10,874,723 Lynx1 Capital Management LP 31 Dec 2024
FMR LLC 4.9% -58% $15,747,811 -$20,861,062 10,225,851 -57% FMR LLC 28 Feb 2025

As of 31 Dec 2025, 169 institutional investors reported holding 162,689,328 shares of Allogene Therapeutics, Inc. - Common Stock (ALLO). This represents 71% of the company’s total 228,416,724 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Allogene Therapeutics, Inc. - Common Stock (ALLO) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Pfizer Inc 9.6% 22,032,040 0% 13% $30,183,895
TPG GP A, LLC 8.2% 18,716,306 0% 0.95% $25,641,339
BlackRock, Inc. 7.7% 17,676,029 +0.92% 0% $24,216,160
CITADEL ADVISORS LLC 5.3% 12,111,420 -13% 0.01% $16,592,646
VANGUARD GROUP INC 4.1% 9,251,609 +2.6% 0% $12,674,704
PRIMECAP MANAGEMENT CO/CA/ 3.6% 8,139,840 +15% 0.01% $11,151,581
Patient Square Capital LP 2.2% 4,963,756 +66% 1.5% $6,800,346
GEODE CAPITAL MANAGEMENT, LLC 1.7% 3,932,910 +2.6% 0% $5,388,905
Frazier Life Sciences Management, L.P. 1.7% 3,868,750 0% 0.14% $5,300,188
Woodline Partners LP 1.5% 3,500,499 -20% 0.02% $4,795,684
TWO SIGMA INVESTMENTS, LP 1.5% 3,423,441 +1.2% 0.01% $4,690,114
PRICE T ROWE ASSOCIATES INC /MD/ 1.4% 3,209,275 -13% 0% $4,398,000
Wildcat Capital Management, LLC 1.3% 2,920,787 0% 2.9% $4,001,478
TWO SIGMA ADVISERS, LP 1.3% 2,890,200 +3.9% 0.01% $3,959,574
STATE STREET CORP 1.2% 2,761,400 +0.22% 0% $3,783,118
Kalehua Capital Management LLC 1.1% 2,546,129 0% 3.5% $3,488,197
Candriam S.C.A. 1% 2,305,644 0.02% $3,158,867
GOLDMAN SACHS GROUP INC 1% 2,289,458 +90% 0% $3,136,557
RENAISSANCE TECHNOLOGIES LLC 0.96% 2,187,084 -24% 0% $2,996,305
JANE STREET GROUP, LLC 0.95% 2,160,383 +78% 0% $2,959,725
Aberdeen Group plc 0.91% 2,086,332 +32% 0% $2,858,275
MILLENNIUM MANAGEMENT LLC 0.81% 1,841,307 -46% 0% $2,522,591
FMR LLC 0.63% 1,445,761 +103% 0% $1,980,692
AQR CAPITAL MANAGEMENT LLC 0.63% 1,429,247 -23% 0% $1,958,068
UBS Group AG 0.61% 1,389,593 -61% 0% $1,903,743

Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 177,793 $437,853 +$156,397 $2.44 10
2025 Q4 162,689,328 $222,787,071 +$240,755 $1.37 169
2025 Q3 162,089,712 $201,004,443 -$24,367,010 $1.24 167
2025 Q2 183,617,614 $207,883,293 -$15,409,926 $1.13 153
2025 Q1 196,986,783 $288,577,139 +$11,150,657 $1.46 167
2024 Q4 188,657,885 $401,850,158 -$12,907,825 $2.13 170
2024 Q3 164,371,652 $460,365,265 -$1,917,859 $2.80 152
2024 Q2 165,184,059 $384,891,280 +$75,138,227 $2.33 169
2024 Q1 131,205,694 $586,006,096 +$44,997,765 $4.47 158
2023 Q4 122,248,338 $392,448,357 -$24,859,731 $3.21 167
2023 Q3 130,384,371 $413,319,837 -$17,479,237 $3.17 152
2023 Q2 133,404,417 $662,853,148 +$77,627,682 $4.97 168
2023 Q1 117,863,372 $582,311,658 +$28,545,426 $4.94 174
2022 Q4 111,615,016 $701,714,273 +$16,748,007 $6.29 166
2022 Q3 106,389,695 $1,148,387,442 +$56,535,530 $10.80 182
2022 Q2 100,792,050 $1,148,985,365 +$110,979,207 $11.40 155
2022 Q1 91,688,120 $835,872,818 +$16,130,116 $9.11 173
2021 Q4 85,813,394 $1,280,601,899 -$105,097,078 $14.92 168
2021 Q3 86,172,174 $2,214,699,254 +$36,168,155 $25.70 165
2021 Q2 86,340,537 $2,251,293,398 -$84,504,708 $26.08 175
2021 Q1 86,575,661 $3,055,834,294 -$11,800,278 $35.30 167
2020 Q4 87,569,716 $2,210,441,766 +$86,472,875 $25.24 160
2020 Q3 83,175,052 $3,136,521,357 -$164,131,449 $37.71 158
2020 Q2 86,937,058 $3,722,235,026 +$671,195,013 $42.82 170
2020 Q1 73,747,853 $1,390,700,983 +$46,546,025 $19.44 115
2019 Q4 71,621,156 $1,860,741,066 +$73,711,322 $25.98 114
2019 Q3 68,693,966 $1,760,955,637 +$43,711,782 $27.26 94
2019 Q2 68,882,259 $1,691,632,297 +$152,108,493 $26.85 94
2019 Q1 65,390,655 $1,661,573,471 +$80,500,361 $28.91 85
2018 Q4 54,998,315 $1,469,849,010 +$1,469,849,001 $26.93 78
2016 Q2 0 $0 -$115,000 $2.44 0
2016 Q1 4,033 $115,000 $28.51 1

Sponsored